IRIS
GALETTI, Maricla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.330
EU - Europa 3.539
AS - Asia 3.217
SA - Sud America 519
AF - Africa 184
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.241
SG - Singapore 1.273
CN - Cina 1.138
IT - Italia 1.005
FI - Finlandia 548
IE - Irlanda 478
SE - Svezia 427
BR - Brasile 418
DE - Germania 318
HK - Hong Kong 240
VN - Vietnam 194
UA - Ucraina 138
NL - Olanda 121
GB - Regno Unito 105
ZA - Sudafrica 101
TR - Turchia 94
IN - India 92
FR - Francia 90
RU - Federazione Russa 90
CA - Canada 55
AT - Austria 51
CI - Costa d'Avorio 48
AR - Argentina 42
BE - Belgio 40
PL - Polonia 34
ES - Italia 28
KR - Corea 25
BD - Bangladesh 24
ID - Indonesia 24
MX - Messico 24
EC - Ecuador 17
JP - Giappone 15
CZ - Repubblica Ceca 13
IQ - Iraq 13
CO - Colombia 12
PK - Pakistan 12
MA - Marocco 11
UZ - Uzbekistan 11
LT - Lituania 10
IR - Iran 7
PY - Paraguay 7
TN - Tunisia 7
VE - Venezuela 7
AL - Albania 6
AZ - Azerbaigian 6
CH - Svizzera 6
HU - Ungheria 6
BO - Bolivia 5
KE - Kenya 5
KG - Kirghizistan 5
NP - Nepal 5
CL - Cile 4
DO - Repubblica Dominicana 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
PE - Perù 4
PS - Palestinian Territory 4
AE - Emirati Arabi Uniti 3
LB - Libano 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PT - Portogallo 3
RO - Romania 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
DZ - Algeria 2
EE - Estonia 2
GR - Grecia 2
LU - Lussemburgo 2
LV - Lettonia 2
MY - Malesia 2
OM - Oman 2
SA - Arabia Saudita 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TJ - Tagikistan 2
AD - Andorra 1
BW - Botswana 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KW - Kuwait 1
LK - Sri Lanka 1
NG - Nigeria 1
QA - Qatar 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.794
Salva come PNG Salva come JPEG
Città #
Singapore 638
Dallas 584
Ashburn 486
Dublin 478
Chandler 458
Parma 364
Santa Clara 310
Ann Arbor 273
Beijing 273
Hong Kong 240
Jacksonville 158
Dearborn 153
Boardman 135
Shanghai 113
Munich 104
New York 103
Los Angeles 97
Nanjing 97
Johannesburg 96
Hefei 95
Chicago 75
Princeton 74
Ho Chi Minh City 72
Izmir 72
Milan 68
Bremen 56
San Mateo 51
Abidjan 48
Helsinki 47
Wilmington 47
São Paulo 46
Vienna 44
Moscow 42
Hanoi 39
Shenyang 39
Nanchang 36
Bologna 33
Buffalo 32
Columbus 31
Kunming 30
Rome 29
Tianjin 29
Des Moines 28
Marseille 28
Warsaw 28
Jinan 27
Modena 27
Seattle 25
Seoul 24
Toronto 24
Brussels 23
London 23
The Dalles 23
Turku 23
Hebei 21
Jakarta 21
Reggio Emilia 21
Phoenix 20
Frankfurt am Main 19
Houston 19
Denver 18
Guangzhou 18
Nuremberg 17
Stockholm 16
Brasília 15
Brooklyn 15
Poplar 15
Redmond 15
Amsterdam 14
Changsha 14
Chennai 14
Jiaxing 14
Rio de Janeiro 14
Tokyo 14
Boston 13
Council Bluffs 13
Manchester 13
Montreal 13
Norwalk 13
Pune 13
Verona 13
Zhengzhou 13
Düsseldorf 12
Leawood 12
Wayne 12
Woodbridge 12
Tashkent 11
Brescia 10
Dong Ket 10
Florence 10
Orem 10
Atlanta 9
Augusta 9
Curitiba 9
Genoa 9
Haiphong 9
Ankara 8
Bari 8
Bengaluru 8
Fremont 8
Totale 7.212
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 225
Highly-defined bioprinting of long-term vascularized scaffolds with Bio-Trap: Complex geometry functionalization and process parameters with computer aided tissue engineering 220
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 218
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 205
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 203
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats 200
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 183
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 179
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 177
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 174
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation 166
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 162
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 162
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 161
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 160
Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(II) complexes on p53 and p53-null tumour cell lines 159
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 158
Nanoparticles exposure: In-vitro and in-vivo investigation to evaluate cardiovascu1ar risk factors in normal and failing cardiac tissue [Esposizione a nanoparticelle: Studi in-vitro ed in-vivo per valutare i fattori di rischio cardiovascolari in cuori normali e patologici] 157
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 154
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 153
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 151
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 150
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 148
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 147
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 147
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 146
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 146
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 146
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 144
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 143
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 142
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 142
Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles 141
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 139
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 136
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 134
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 133
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 131
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 131
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 131
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 129
New MDR1 inhibitors for overcoming multidrug resistance 129
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 128
SiO2/SiC core-shell nanowires for nanomedicine applications 127
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 126
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 126
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 125
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 123
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 121
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 121
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 119
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
Cardiac kinematic parameters computed from video of in situ beating heart 119
SiO2/SiC core-shell nanowires for nanomedicine applications 117
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 114
Study and characterization of a new magnetic nanocomposite system for nanomedicine 112
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 112
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 109
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 105
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 103
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 102
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 101
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 99
Interaction between occupational radon exposure and tobacco smoke: a systematic review 97
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 95
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 94
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 92
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 89
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 88
Synergistic activity of letrozole and sorafenib on breast cancer cells 86
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 86
Optimizing EGFR inhibitor treatment in non small cell lung cancer 85
Chapter 9 - Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes 83
The inducible coexpression of p53 and FHIT has a synergistic anti-proliferative effect in calu-1 lung cancer cell line 81
In vitro characterization of efflux and metabolism of gefitinib 81
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 76
New irreversible inhibitors of EGFR tyrosine kinase activity to circumvent iressa resistance 75
Effect of inducile FHIT and p53 expression in Calu-1 lung cancer cell line. 72
Espressione inducibile di Fhit e p53 in cellule di carcinoma polmonare non a piccole cellule 67
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 65
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 63
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 57
null 31
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 13
Totale 11.991
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.000
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021387 0 0 0 0 0 26 46 44 106 23 101 41
2021/2022427 30 19 22 29 15 9 56 36 23 24 24 140
2022/20231.835 151 220 119 107 171 204 18 137 586 17 78 27
2023/2024969 44 75 48 37 67 174 77 87 39 59 105 157
2024/20252.729 128 126 161 205 248 304 182 131 347 220 241 436
2025/20263.261 477 486 846 609 777 66 0 0 0 0 0 0
Totale 11.991